title: [Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
abstract: For the treatment of type 2 diabetes we now have available a wide spectrum of oral antidiabetic agents and insulins that make it possible to offer the patient an individualized, pathophysiologically oriented therapy. Such treatment should be oriented to the two basic defects--insulin resistance and impaired early secretion of insulin--which can be assessed on the basis of fasting and postprandial blood sugar. Since monotherapy rarely suffices to correct the complex dysregulation, when close-to normalization of the glucose triad fasting blood glucose, postprandial blood glucose and HbA1C fails, early application of complementary combinations offer advantages, with preference being given to metformin in the overweight patient. This also applies to the combination with insulin.
authors.affiliation: Zentrum für Klinische Studien, GWT-TU Dresden mbH.
authors.forename: M
authors.initials: M
authors.lastname: Hanefeld
authors.forename: S
authors.initials: S
authors.lastname: Fischer
mesh_terms: D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives; D020909:Acarbose / Q000008:administration & dosage / Q000627:therapeutic use; D000284:Administration, Oral; D001786:Blood Glucose / Q000032:analysis*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005215:Fasting; D005944:Glucosamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D050112:Imino Pyranoses; D007328:Insulin / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D007333:Insulin Resistance; D000078790:Insulin Secretion; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use; D009765:Obesity / Q000150:complications; D000077205:Pioglitazone; D012307:Risk Factors; D000077154:Rosiglitazone; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use; D045162:Thiazolidinediones; D013997:Time Factors
chemical_list: D017485:1-Deoxynojirimycin; D020909:Acarbose; D001786:Blood Glucose; D005944:Glucosamine; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D050112:Imino Pyranoses; D007328:Insulin; D008687:Metformin; D000077205:Pioglitazone; D000077154:Rosiglitazone; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; C045621:miglitol